U.S. Markets open in 27 mins

Evogene Ltd. (EVGN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
6.24+0.45 (+7.77%)
At close: 4:00PM EST

6.18 -0.06 (-0.96%)
Before hours: 9:03AM EST

Evogene Ltd.

13 Gad Feinstein Street
Park Rehovot PO Box 2100
Rehovot 7612002
972 8 931 1900

Full Time Employees143

Key Executives

NameTitlePayExercisedYear Born
Mr. Ofer HavivCEO, Pres & Director442kN/A1966
Ms. Dorit KreinerChief Financial Officer232kN/AN/A
Mr. Mark KapelExec. VP of Technology234kN/A1977
Dr. Eyal EmmanuelChief Scientific OfficerN/AN/A1973
Rivka NeufeldInvestor Relation & PR Mang.N/AN/AN/A
Sassi MasliahVP of Legal Affairs & Company Sec.N/AN/AN/A
Dr. Gaya Loren Ph.D.Exec. VP of Product Devel.N/AN/AN/A
Mr. Douglas A. EisnerChief Exec. Officer of AgPlenus Ltd.N/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Application segment develops enhanced castor bean seeds to serve as a feedstock source for biofuel and other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and multi drug resistant organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.

Corporate Governance

Evogene Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.